Pulmonary Medicine

Anderson, United States

Pulmonary Medicine

Anderson, United States

Time filter

Source Type

Acute and Chronic Benefits Demonstrated with INOpulse in Patients with PH-IPF; Patients Achieved Statistically Significant Increases in Blood Vessel Volume; Consistent Improvements were Observed in Hemodynamics, 6MWD and Composite Endpoints of Oxygen Saturation and 6MWD Preliminary Results from an Ongoing Study in PH-COPD Support a Consistent Improvement in Vasodilation and Meaningful Reduction in Pulmonary Artery Pressures with 4 Weeks of INOpulse Treatment WARREN, N.J., May 22, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the presentation of new clinical data from a Phase 2 clinical trial that investigated INOpulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension (PH-IPF) at the American Thoracic Society (ATS) 113th International Conference, currently taking place in Washington DC.  The company also presented preliminary data from a second, ongoing study evaluating INOpulse in COPD patients with Pulmonary Hypertension (PH-COPD). “Pulmonary Hypertension with IPF or COPD has no approved therapies and has been associated with increased hospitalizations and mortality.  The therapies used in other pulmonary hypertension populations, which act systemically, have failed to show a benefit for these patients, creating a critical unmet need for effective and safe long-term treatment options,” said Prof. W. De Backer MD, Director in the Department of Pulmonary Medicine, University Hospital and University of Antwerp. “Pulsed iNO has a potentially unique and distinguishing advantage as the data from these trials shows that it can provide selective vasodilation to the well-functioning parts of the lung, allowing for improvement in hemodynamic measures as well as increased exercise capacity without worsening oxygenation.” The PH-IPF study was a proof of concept study (n=4) designed to evaluate the ability of pulsed inhaled nitric oxide (iNO) to provide selective vasodilation as well as assess the potential for improvement in hemodynamics and exercise capacity in PH-IPF patients.   The study met its primary endpoint showing an average of 15.3% increase in blood vessel volume (p<0.001) during acute inhalation of iNO as well as showing a significant association between ventilation and vasodilation, demonstrating the ability of INOpulse to provide selective vasodilation to the better ventilated areas of the lung.  The study showed consistent benefit in hemodynamics with a clinically meaningful average reduction of 14% in systolic pulmonary arterial pressure (sPAP) with acute exposure to iNO.  The study also assessed the chronic effects of iNO on exercise capacity showing an average 75 meter improvement in 6MWD and consistent improvement of approximately 80 m% in composite endpoints of 6MWD and oxygen saturation with four weeks of treatment.  The study assessed both the iNO 75 and iNO 30 dose, supporting iNO 30 as a potentially safe and effective dose. The next step in this program will be to conduct a larger Phase 2b study to inform the design of a pivotal registration trial. The company also shared preliminary results of an ongoing PH-COPD study (n=10) designed to evaluate the acute effects of pulsed iNO on vasodilation as well as the chronic effect on hemodynamics and exercise tolerance.  The interim data results from the first four patients showed a significant association between ventilation and vasodilation on acute treatment with iNO, suggesting that regions with better ventilation experience greater vasodilation.  In addition, a meaningful reduction in sPAP (average 17.4%) was seen on all patients with chronic treatment of iNO.  The full study results are expected around the middle of 2017. About the American Thoracic Society The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases. The ATS 113th International Conference is taking place at the Walter E. Washington Convention Center in Washington DC, May 19-24, 2017.  Additional information on the ATS 113th International Conference can be found at http://conference.thoracic.org. About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF), both of which are in Phase 2 development.  For more information, please visit www.bellerophon.com.


Acute and Chronic Benefits Demonstrated with INOpulse in Patients with PH-IPF; Patients Achieved Statistically Significant Increases in Blood Vessel Volume; Consistent Improvements were Observed in Hemodynamics, 6MWD and Composite Endpoints of Oxygen Saturation and 6MWD Preliminary Results from an Ongoing Study in PH-COPD Support a Consistent Improvement in Vasodilation and Meaningful Reduction in Pulmonary Artery Pressures with 4 Weeks of INOpulse Treatment WARREN, N.J., May 22, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the presentation of new clinical data from a Phase 2 clinical trial that investigated INOpulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension (PH-IPF) at the American Thoracic Society (ATS) 113th International Conference, currently taking place in Washington DC.  The company also presented preliminary data from a second, ongoing study evaluating INOpulse in COPD patients with Pulmonary Hypertension (PH-COPD). “Pulmonary Hypertension with IPF or COPD has no approved therapies and has been associated with increased hospitalizations and mortality.  The therapies used in other pulmonary hypertension populations, which act systemically, have failed to show a benefit for these patients, creating a critical unmet need for effective and safe long-term treatment options,” said Prof. W. De Backer MD, Director in the Department of Pulmonary Medicine, University Hospital and University of Antwerp. “Pulsed iNO has a potentially unique and distinguishing advantage as the data from these trials shows that it can provide selective vasodilation to the well-functioning parts of the lung, allowing for improvement in hemodynamic measures as well as increased exercise capacity without worsening oxygenation.” The PH-IPF study was a proof of concept study (n=4) designed to evaluate the ability of pulsed inhaled nitric oxide (iNO) to provide selective vasodilation as well as assess the potential for improvement in hemodynamics and exercise capacity in PH-IPF patients.   The study met its primary endpoint showing an average of 15.3% increase in blood vessel volume (p<0.001) during acute inhalation of iNO as well as showing a significant association between ventilation and vasodilation, demonstrating the ability of INOpulse to provide selective vasodilation to the better ventilated areas of the lung.  The study showed consistent benefit in hemodynamics with a clinically meaningful average reduction of 14% in systolic pulmonary arterial pressure (sPAP) with acute exposure to iNO.  The study also assessed the chronic effects of iNO on exercise capacity showing an average 75 meter improvement in 6MWD and consistent improvement of approximately 80 m% in composite endpoints of 6MWD and oxygen saturation with four weeks of treatment.  The study assessed both the iNO 75 and iNO 30 dose, supporting iNO 30 as a potentially safe and effective dose. The next step in this program will be to conduct a larger Phase 2b study to inform the design of a pivotal registration trial. The company also shared preliminary results of an ongoing PH-COPD study (n=10) designed to evaluate the acute effects of pulsed iNO on vasodilation as well as the chronic effect on hemodynamics and exercise tolerance.  The interim data results from the first four patients showed a significant association between ventilation and vasodilation on acute treatment with iNO, suggesting that regions with better ventilation experience greater vasodilation.  In addition, a meaningful reduction in sPAP (average 17.4%) was seen on all patients with chronic treatment of iNO.  The full study results are expected around the middle of 2017. About the American Thoracic Society The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases. The ATS 113th International Conference is taking place at the Walter E. Washington Convention Center in Washington DC, May 19-24, 2017.  Additional information on the ATS 113th International Conference can be found at http://conference.thoracic.org. About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF), both of which are in Phase 2 development.  For more information, please visit www.bellerophon.com.


Acute and Chronic Benefits Demonstrated with INOpulse in Patients with PH-IPF; Patients Achieved Statistically Significant Increases in Blood Vessel Volume; Consistent Improvements were Observed in Hemodynamics, 6MWD and Composite Endpoints of Oxygen Saturation and 6MWD Preliminary Results from an Ongoing Study in PH-COPD Support a Consistent Improvement in Vasodilation and Meaningful Reduction in Pulmonary Artery Pressures with 4 Weeks of INOpulse Treatment WARREN, N.J., May 22, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the presentation of new clinical data from a Phase 2 clinical trial that investigated INOpulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension (PH-IPF) at the American Thoracic Society (ATS) 113th International Conference, currently taking place in Washington DC.  The company also presented preliminary data from a second, ongoing study evaluating INOpulse in COPD patients with Pulmonary Hypertension (PH-COPD). “Pulmonary Hypertension with IPF or COPD has no approved therapies and has been associated with increased hospitalizations and mortality.  The therapies used in other pulmonary hypertension populations, which act systemically, have failed to show a benefit for these patients, creating a critical unmet need for effective and safe long-term treatment options,” said Prof. W. De Backer MD, Director in the Department of Pulmonary Medicine, University Hospital and University of Antwerp. “Pulsed iNO has a potentially unique and distinguishing advantage as the data from these trials shows that it can provide selective vasodilation to the well-functioning parts of the lung, allowing for improvement in hemodynamic measures as well as increased exercise capacity without worsening oxygenation.” The PH-IPF study was a proof of concept study (n=4) designed to evaluate the ability of pulsed inhaled nitric oxide (iNO) to provide selective vasodilation as well as assess the potential for improvement in hemodynamics and exercise capacity in PH-IPF patients.   The study met its primary endpoint showing an average of 15.3% increase in blood vessel volume (p<0.001) during acute inhalation of iNO as well as showing a significant association between ventilation and vasodilation, demonstrating the ability of INOpulse to provide selective vasodilation to the better ventilated areas of the lung.  The study showed consistent benefit in hemodynamics with a clinically meaningful average reduction of 14% in systolic pulmonary arterial pressure (sPAP) with acute exposure to iNO.  The study also assessed the chronic effects of iNO on exercise capacity showing an average 75 meter improvement in 6MWD and consistent improvement of approximately 80 m% in composite endpoints of 6MWD and oxygen saturation with four weeks of treatment.  The study assessed both the iNO 75 and iNO 30 dose, supporting iNO 30 as a potentially safe and effective dose. The next step in this program will be to conduct a larger Phase 2b study to inform the design of a pivotal registration trial. The company also shared preliminary results of an ongoing PH-COPD study (n=10) designed to evaluate the acute effects of pulsed iNO on vasodilation as well as the chronic effect on hemodynamics and exercise tolerance.  The interim data results from the first four patients showed a significant association between ventilation and vasodilation on acute treatment with iNO, suggesting that regions with better ventilation experience greater vasodilation.  In addition, a meaningful reduction in sPAP (average 17.4%) was seen on all patients with chronic treatment of iNO.  The full study results are expected around the middle of 2017. About the American Thoracic Society The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases. The ATS 113th International Conference is taking place at the Walter E. Washington Convention Center in Washington DC, May 19-24, 2017.  Additional information on the ATS 113th International Conference can be found at http://conference.thoracic.org. About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF), both of which are in Phase 2 development.  For more information, please visit www.bellerophon.com.


Acute and Chronic Benefits Demonstrated with INOpulse in Patients with PH-IPF; Patients Achieved Statistically Significant Increases in Blood Vessel Volume; Consistent Improvements were Observed in Hemodynamics, 6MWD and Composite Endpoints of Oxygen Saturation and 6MWD Preliminary Results from an Ongoing Study in PH-COPD Support a Consistent Improvement in Vasodilation and Meaningful Reduction in Pulmonary Artery Pressures with 4 Weeks of INOpulse Treatment WARREN, N.J., May 22, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the presentation of new clinical data from a Phase 2 clinical trial that investigated INOpulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension (PH-IPF) at the American Thoracic Society (ATS) 113th International Conference, currently taking place in Washington DC.  The company also presented preliminary data from a second, ongoing study evaluating INOpulse in COPD patients with Pulmonary Hypertension (PH-COPD). “Pulmonary Hypertension with IPF or COPD has no approved therapies and has been associated with increased hospitalizations and mortality.  The therapies used in other pulmonary hypertension populations, which act systemically, have failed to show a benefit for these patients, creating a critical unmet need for effective and safe long-term treatment options,” said Prof. W. De Backer MD, Director in the Department of Pulmonary Medicine, University Hospital and University of Antwerp. “Pulsed iNO has a potentially unique and distinguishing advantage as the data from these trials shows that it can provide selective vasodilation to the well-functioning parts of the lung, allowing for improvement in hemodynamic measures as well as increased exercise capacity without worsening oxygenation.” The PH-IPF study was a proof of concept study (n=4) designed to evaluate the ability of pulsed inhaled nitric oxide (iNO) to provide selective vasodilation as well as assess the potential for improvement in hemodynamics and exercise capacity in PH-IPF patients.   The study met its primary endpoint showing an average of 15.3% increase in blood vessel volume (p<0.001) during acute inhalation of iNO as well as showing a significant association between ventilation and vasodilation, demonstrating the ability of INOpulse to provide selective vasodilation to the better ventilated areas of the lung.  The study showed consistent benefit in hemodynamics with a clinically meaningful average reduction of 14% in systolic pulmonary arterial pressure (sPAP) with acute exposure to iNO.  The study also assessed the chronic effects of iNO on exercise capacity showing an average 75 meter improvement in 6MWD and consistent improvement of approximately 80 m% in composite endpoints of 6MWD and oxygen saturation with four weeks of treatment.  The study assessed both the iNO 75 and iNO 30 dose, supporting iNO 30 as a potentially safe and effective dose. The next step in this program will be to conduct a larger Phase 2b study to inform the design of a pivotal registration trial. The company also shared preliminary results of an ongoing PH-COPD study (n=10) designed to evaluate the acute effects of pulsed iNO on vasodilation as well as the chronic effect on hemodynamics and exercise tolerance.  The interim data results from the first four patients showed a significant association between ventilation and vasodilation on acute treatment with iNO, suggesting that regions with better ventilation experience greater vasodilation.  In addition, a meaningful reduction in sPAP (average 17.4%) was seen on all patients with chronic treatment of iNO.  The full study results are expected around the middle of 2017. About the American Thoracic Society The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases. The ATS 113th International Conference is taking place at the Walter E. Washington Convention Center in Washington DC, May 19-24, 2017.  Additional information on the ATS 113th International Conference can be found at http://conference.thoracic.org. About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF), both of which are in Phase 2 development.  For more information, please visit www.bellerophon.com.


Acute and Chronic Benefits Demonstrated with INOpulse in Patients with PH-IPF; Patients Achieved Statistically Significant Increases in Blood Vessel Volume; Consistent Improvements were Observed in Hemodynamics, 6MWD and Composite Endpoints of Oxygen Saturation and 6MWD Preliminary Results from an Ongoing Study in PH-COPD Support a Consistent Improvement in Vasodilation and Meaningful Reduction in Pulmonary Artery Pressures with 4 Weeks of INOpulse Treatment WARREN, N.J., May 22, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the presentation of new clinical data from a Phase 2 clinical trial that investigated INOpulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension (PH-IPF) at the American Thoracic Society (ATS) 113th International Conference, currently taking place in Washington DC.  The company also presented preliminary data from a second, ongoing study evaluating INOpulse in COPD patients with Pulmonary Hypertension (PH-COPD). “Pulmonary Hypertension with IPF or COPD has no approved therapies and has been associated with increased hospitalizations and mortality.  The therapies used in other pulmonary hypertension populations, which act systemically, have failed to show a benefit for these patients, creating a critical unmet need for effective and safe long-term treatment options,” said Prof. W. De Backer MD, Director in the Department of Pulmonary Medicine, University Hospital and University of Antwerp. “Pulsed iNO has a potentially unique and distinguishing advantage as the data from these trials shows that it can provide selective vasodilation to the well-functioning parts of the lung, allowing for improvement in hemodynamic measures as well as increased exercise capacity without worsening oxygenation.” The PH-IPF study was a proof of concept study (n=4) designed to evaluate the ability of pulsed inhaled nitric oxide (iNO) to provide selective vasodilation as well as assess the potential for improvement in hemodynamics and exercise capacity in PH-IPF patients.   The study met its primary endpoint showing an average of 15.3% increase in blood vessel volume (p<0.001) during acute inhalation of iNO as well as showing a significant association between ventilation and vasodilation, demonstrating the ability of INOpulse to provide selective vasodilation to the better ventilated areas of the lung.  The study showed consistent benefit in hemodynamics with a clinically meaningful average reduction of 14% in systolic pulmonary arterial pressure (sPAP) with acute exposure to iNO.  The study also assessed the chronic effects of iNO on exercise capacity showing an average 75 meter improvement in 6MWD and consistent improvement of approximately 80 m% in composite endpoints of 6MWD and oxygen saturation with four weeks of treatment.  The study assessed both the iNO 75 and iNO 30 dose, supporting iNO 30 as a potentially safe and effective dose. The next step in this program will be to conduct a larger Phase 2b study to inform the design of a pivotal registration trial. The company also shared preliminary results of an ongoing PH-COPD study (n=10) designed to evaluate the acute effects of pulsed iNO on vasodilation as well as the chronic effect on hemodynamics and exercise tolerance.  The interim data results from the first four patients showed a significant association between ventilation and vasodilation on acute treatment with iNO, suggesting that regions with better ventilation experience greater vasodilation.  In addition, a meaningful reduction in sPAP (average 17.4%) was seen on all patients with chronic treatment of iNO.  The full study results are expected around the middle of 2017. About the American Thoracic Society The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases. The ATS 113th International Conference is taking place at the Walter E. Washington Convention Center in Washington DC, May 19-24, 2017.  Additional information on the ATS 113th International Conference can be found at http://conference.thoracic.org. About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF), both of which are in Phase 2 development.  For more information, please visit www.bellerophon.com.


NEW YORK, May 03, 2017 (GLOBE NEWSWIRE) -- The American Health Council has chosen Dr. Amanda D. Maynard, Internist at Ohio Health, as one of the "Best Doctor's in America" for 2017. Recognized for her knowledge and expertise in Internal Medicine, Adult Medicine, Pulmonary Medicine and Osteopathic Manipulation, Dr. Maynard has been awarded the "Leaders in Medicine" award among Ohio doctors. Selection for the American Health Council’s “Leaders in Medicine” award is reserved for those individuals who have exhibited exemplary conduct in their field. These doctors and medical educators serve as the guiding light for advancement from the classroom to the consultation room to the operating room. Only those who master the key roles that drive patient care — advocate, collaborator, communicator, decision maker, expert, manager, scholar — are deserving to be named the “Best Doctors in America.” With experience in the field of Internal Medicine, Dr. Maynard offers valuable insight in her role as Internist at Ohio Health. Established in Ohio in 1891, Ohio Health is a non-for-profit, faith-based hospitals and healthcare organization. Focused on the improvement of the community through the delivery of quality, convenient, and timely healthcare, Ohio Health was named to the 2013 Top Hospital list from the Leapfrog Group. Board Certified by the American Osteopathic Board of Internal Medicine, Dr. Maynard’s day-to-day responsibilities include chronic acute care for patients age 16 and up tackling hypertension, diabetes, asthma/chronic obstructive pulmonary disease and osteopathic medicine. Maintaining consecutive recognition as the Best Doctors in America for 2015 and 2016, Dr. Maynard has completed a fellowship with the American College of Physicians, and has served as a Clinical Assistant Professor at Ohio University of Osteopathic Medicine. Following graduation with her medical degree from West Virginia School of Osteopathic Medicine in 2007, Dr. Maynard completed an internship in 2008 and residency in Internal Medicine at Doctors Hospital in 2010. Dr. Maynard maintains membership with the American College of Physicians, The American Osteopathic Association, The Ohio Osteopathic Association, The American College of Osteopathic Internists, and The American Board of Osteopathic Internal Medicine. Looking back, Dr. Maynard attributes her success to her dedication, strong work ethic, and the support from her parents who helped her to be involved in the medical field at a young age. Dr. Maynard chose the field of Internal Medicine after working at the front desk of a hospital in high school and later becoming an ER technician. In her free time, Dr. Maynard enjoys running marathons, horseback riding, paddle boarding, boating and spending time with her husband and two English Bulldogs (Gus and Lula). Considering the future, Dr. Maynard hopes to do administrative work for Ohio Health, to help to make changes to the VA hospitals, and to provide better healthcare and access to veterans. The American Health Council is the nation’s only organization with a constituency representative of all sectors of the healthcare industry. From the coasts to the heartland, the American Health Council has drawn Affiliates from major metropolitan hubs and small communities. These Affiliates span generations and have reached different stages of their careers — from recent graduates to retirees. More information about the American Health Council and its mission can be found at: http://americanhealthcouncil.org Additionally, the American Health Council strives to provide recognition and support for those individuals making the difference in patients’ lives day in and day out. Throughout 2017, the AHC is honoring America’s Best Doctors and Nurses. The American Health Council’s “Best in Medicine” and “Best in Nursing” awards programs honor the individuals and institutions that have contributed significantly to medicine and nursing, as well as the training and education of physicians and nurses. The most current selections for these honors may be viewed here: http://bestinmedicine.org and http://bestinnursing.org.


NEW YORK, May 03, 2017 (GLOBE NEWSWIRE) -- The American Health Council has chosen Dr. Amanda D. Maynard, Internist at Ohio Health, as one of the "Best Doctor's in America" for 2017. Recognized for her knowledge and expertise in Internal Medicine, Adult Medicine, Pulmonary Medicine and Osteopathic Manipulation, Dr. Maynard has been awarded the "Leaders in Medicine" award among Ohio doctors. Selection for the American Health Council’s “Leaders in Medicine” award is reserved for those individuals who have exhibited exemplary conduct in their field. These doctors and medical educators serve as the guiding light for advancement from the classroom to the consultation room to the operating room. Only those who master the key roles that drive patient care — advocate, collaborator, communicator, decision maker, expert, manager, scholar — are deserving to be named the “Best Doctors in America.” With experience in the field of Internal Medicine, Dr. Maynard offers valuable insight in her role as Internist at Ohio Health. Established in Ohio in 1891, Ohio Health is a non-for-profit, faith-based hospitals and healthcare organization. Focused on the improvement of the community through the delivery of quality, convenient, and timely healthcare, Ohio Health was named to the 2013 Top Hospital list from the Leapfrog Group. Board Certified by the American Osteopathic Board of Internal Medicine, Dr. Maynard’s day-to-day responsibilities include chronic acute care for patients age 16 and up tackling hypertension, diabetes, asthma/chronic obstructive pulmonary disease and osteopathic medicine. Maintaining consecutive recognition as the Best Doctors in America for 2015 and 2016, Dr. Maynard has completed a fellowship with the American College of Physicians, and has served as a Clinical Assistant Professor at Ohio University of Osteopathic Medicine. Following graduation with her medical degree from West Virginia School of Osteopathic Medicine in 2007, Dr. Maynard completed an internship in 2008 and residency in Internal Medicine at Doctors Hospital in 2010. Dr. Maynard maintains membership with the American College of Physicians, The American Osteopathic Association, The Ohio Osteopathic Association, The American College of Osteopathic Internists, and The American Board of Osteopathic Internal Medicine. Looking back, Dr. Maynard attributes her success to her dedication, strong work ethic, and the support from her parents who helped her to be involved in the medical field at a young age. Dr. Maynard chose the field of Internal Medicine after working at the front desk of a hospital in high school and later becoming an ER technician. In her free time, Dr. Maynard enjoys running marathons, horseback riding, paddle boarding, boating and spending time with her husband and two English Bulldogs (Gus and Lula). Considering the future, Dr. Maynard hopes to do administrative work for Ohio Health, to help to make changes to the VA hospitals, and to provide better healthcare and access to veterans. The American Health Council is the nation’s only organization with a constituency representative of all sectors of the healthcare industry. From the coasts to the heartland, the American Health Council has drawn Affiliates from major metropolitan hubs and small communities. These Affiliates span generations and have reached different stages of their careers — from recent graduates to retirees. More information about the American Health Council and its mission can be found at: http://americanhealthcouncil.org Additionally, the American Health Council strives to provide recognition and support for those individuals making the difference in patients’ lives day in and day out. Throughout 2017, the AHC is honoring America’s Best Doctors and Nurses. The American Health Council’s “Best in Medicine” and “Best in Nursing” awards programs honor the individuals and institutions that have contributed significantly to medicine and nursing, as well as the training and education of physicians and nurses. The most current selections for these honors may be viewed here: http://bestinmedicine.org and http://bestinnursing.org.


NEW YORK, May 03, 2017 (GLOBE NEWSWIRE) -- The American Health Council has chosen Dr. Amanda D. Maynard, Internist at Ohio Health, as one of the "Best Doctor's in America" for 2017. Recognized for her knowledge and expertise in Internal Medicine, Adult Medicine, Pulmonary Medicine and Osteopathic Manipulation, Dr. Maynard has been awarded the "Leaders in Medicine" award among Ohio doctors. Selection for the American Health Council’s “Leaders in Medicine” award is reserved for those individuals who have exhibited exemplary conduct in their field. These doctors and medical educators serve as the guiding light for advancement from the classroom to the consultation room to the operating room. Only those who master the key roles that drive patient care — advocate, collaborator, communicator, decision maker, expert, manager, scholar — are deserving to be named the “Best Doctors in America.” With experience in the field of Internal Medicine, Dr. Maynard offers valuable insight in her role as Internist at Ohio Health. Established in Ohio in 1891, Ohio Health is a non-for-profit, faith-based hospitals and healthcare organization. Focused on the improvement of the community through the delivery of quality, convenient, and timely healthcare, Ohio Health was named to the 2013 Top Hospital list from the Leapfrog Group. Board Certified by the American Osteopathic Board of Internal Medicine, Dr. Maynard’s day-to-day responsibilities include chronic acute care for patients age 16 and up tackling hypertension, diabetes, asthma/chronic obstructive pulmonary disease and osteopathic medicine. Maintaining consecutive recognition as the Best Doctors in America for 2015 and 2016, Dr. Maynard has completed a fellowship with the American College of Physicians, and has served as a Clinical Assistant Professor at Ohio University of Osteopathic Medicine. Following graduation with her medical degree from West Virginia School of Osteopathic Medicine in 2007, Dr. Maynard completed an internship in 2008 and residency in Internal Medicine at Doctors Hospital in 2010. Dr. Maynard maintains membership with the American College of Physicians, The American Osteopathic Association, The Ohio Osteopathic Association, The American College of Osteopathic Internists, and The American Board of Osteopathic Internal Medicine. Looking back, Dr. Maynard attributes her success to her dedication, strong work ethic, and the support from her parents who helped her to be involved in the medical field at a young age. Dr. Maynard chose the field of Internal Medicine after working at the front desk of a hospital in high school and later becoming an ER technician. In her free time, Dr. Maynard enjoys running marathons, horseback riding, paddle boarding, boating and spending time with her husband and two English Bulldogs (Gus and Lula). Considering the future, Dr. Maynard hopes to do administrative work for Ohio Health, to help to make changes to the VA hospitals, and to provide better healthcare and access to veterans. The American Health Council is the nation’s only organization with a constituency representative of all sectors of the healthcare industry. From the coasts to the heartland, the American Health Council has drawn Affiliates from major metropolitan hubs and small communities. These Affiliates span generations and have reached different stages of their careers — from recent graduates to retirees. More information about the American Health Council and its mission can be found at: http://americanhealthcouncil.org Additionally, the American Health Council strives to provide recognition and support for those individuals making the difference in patients’ lives day in and day out. Throughout 2017, the AHC is honoring America’s Best Doctors and Nurses. The American Health Council’s “Best in Medicine” and “Best in Nursing” awards programs honor the individuals and institutions that have contributed significantly to medicine and nursing, as well as the training and education of physicians and nurses. The most current selections for these honors may be viewed here: http://bestinmedicine.org and http://bestinnursing.org.


NEW YORK, May 03, 2017 (GLOBE NEWSWIRE) -- The American Health Council has chosen Dr. Amanda D. Maynard, Internist at Ohio Health, as one of the "Best Doctor's in America" for 2017. Recognized for her knowledge and expertise in Internal Medicine, Adult Medicine, Pulmonary Medicine and Osteopathic Manipulation, Dr. Maynard has been awarded the "Leaders in Medicine" award among Ohio doctors. Selection for the American Health Council’s “Leaders in Medicine” award is reserved for those individuals who have exhibited exemplary conduct in their field. These doctors and medical educators serve as the guiding light for advancement from the classroom to the consultation room to the operating room. Only those who master the key roles that drive patient care — advocate, collaborator, communicator, decision maker, expert, manager, scholar — are deserving to be named the “Best Doctors in America.” With experience in the field of Internal Medicine, Dr. Maynard offers valuable insight in her role as Internist at Ohio Health. Established in Ohio in 1891, Ohio Health is a non-for-profit, faith-based hospitals and healthcare organization. Focused on the improvement of the community through the delivery of quality, convenient, and timely healthcare, Ohio Health was named to the 2013 Top Hospital list from the Leapfrog Group. Board Certified by the American Osteopathic Board of Internal Medicine, Dr. Maynard’s day-to-day responsibilities include chronic acute care for patients age 16 and up tackling hypertension, diabetes, asthma/chronic obstructive pulmonary disease and osteopathic medicine. Maintaining consecutive recognition as the Best Doctors in America for 2015 and 2016, Dr. Maynard has completed a fellowship with the American College of Physicians, and has served as a Clinical Assistant Professor at Ohio University of Osteopathic Medicine. Following graduation with her medical degree from West Virginia School of Osteopathic Medicine in 2007, Dr. Maynard completed an internship in 2008 and residency in Internal Medicine at Doctors Hospital in 2010. Dr. Maynard maintains membership with the American College of Physicians, The American Osteopathic Association, The Ohio Osteopathic Association, The American College of Osteopathic Internists, and The American Board of Osteopathic Internal Medicine. Looking back, Dr. Maynard attributes her success to her dedication, strong work ethic, and the support from her parents who helped her to be involved in the medical field at a young age. Dr. Maynard chose the field of Internal Medicine after working at the front desk of a hospital in high school and later becoming an ER technician. In her free time, Dr. Maynard enjoys running marathons, horseback riding, paddle boarding, boating and spending time with her husband and two English Bulldogs (Gus and Lula). Considering the future, Dr. Maynard hopes to do administrative work for Ohio Health, to help to make changes to the VA hospitals, and to provide better healthcare and access to veterans. The American Health Council is the nation’s only organization with a constituency representative of all sectors of the healthcare industry. From the coasts to the heartland, the American Health Council has drawn Affiliates from major metropolitan hubs and small communities. These Affiliates span generations and have reached different stages of their careers — from recent graduates to retirees. More information about the American Health Council and its mission can be found at: http://americanhealthcouncil.org Additionally, the American Health Council strives to provide recognition and support for those individuals making the difference in patients’ lives day in and day out. Throughout 2017, the AHC is honoring America’s Best Doctors and Nurses. The American Health Council’s “Best in Medicine” and “Best in Nursing” awards programs honor the individuals and institutions that have contributed significantly to medicine and nursing, as well as the training and education of physicians and nurses. The most current selections for these honors may be viewed here: http://bestinmedicine.org and http://bestinnursing.org.

Loading Pulmonary Medicine collaborators
Loading Pulmonary Medicine collaborators